08:00 , Jan 5, 2015 |  BC Week In Review  |  Company News

Daiichi Sankyo sales and marketing update

Daiichi’s Daiichi Sankyo Espha Co. Ltd. subsidiary launched generic versions of levofloxacin, candesartan cilexetil and IV oxaliplatin in Japan. Daiichi markets levofloxacin, a synthetic broad-spectrum oral fluoroquinolone antibiotic targeting bacterial DNA gyrase and topoisomerase ,...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Cravit levofloxacin regulatory update

Daiichi said that its Daiichi Sankyo Espha Co. Ltd. subsidiary submitted an sNDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for oral Cravit levofloxacin and its generic counterparts to treat pulmonary and other...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

First Pharmaceutical, Daiichi Sankyo, Ranbaxy sales and marketing update

Ranbaxy received rights to market Daiichi's antibacterial agent oral Cravit levofloxacin in Malaysia. First Pharmaceutical, which already markets the antibiotic in the country, will transfer marketing rights to Ranbaxy. First Pharma will continue to market...